Genetic Therapy for Malignant Pleural Mesothelioma:

The clinical responses reported support the study ’ s central hypothesis that blockade of the immune inhibi- tory ligand CD200 by samalizumab promotes anti-tumor activity: serial

Inhibition of FUT8 by genetic ablation reduced cell surface expression of PD-1 and enhanced T cell activation and anti- tumor immune responses ( Table 3